Overview

• The Alliance Medical case-series, presented at EANM 2025, found multiple atypical FDG uptake patterns in patients on GLP-1 agonists that can resemble malignancy or inflammation.
• Misinterpretation of these patterns could lead to unnecessary tests, incorrect cancer staging, and delays in treatment, the researchers warned.
• Investigators do not recommend stopping GLP-1 therapies or changing standard scan preparation and instead call for thorough recording of medication history to aid interpretation.
• There is no UK-specific guidance on this issue, while Australian advice suggests continuing GLP-1s with fasting from midnight, morning scheduling, and good glucose control.
• With about one in eight U.S. adults reporting GLP-1 use and adoption rising, the team is expanding multicenter and international data collection to inform future formal guidance.